Mon, August 28, 2023

Ed Arce Upgraded (AKBA) to Strong Buy and Increased Target to $3.75 on, Aug 28th, 2023

Ed Arce of HC Wainwright & Co., Upgraded "Akebia Therapeutics, Inc." (AKBA) to Strong Buy and Increased Target from $2 to $3.75 on, Aug 28th, 2023.

Ed has made no other calls on AKBA in the last 4 months.



There is 1 other peer that has a rating on AKBA. Out of the 1 peers that are also analyzing AKBA, 0 agree with Ed's Rating of Hold.



This is the rating of the analyst that currently disagrees with Ed


  • Christopher Raymond of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $4 on, Wednesday, May 31st, 2023